AKT1 and prostate cancer: Despite promising results in early preclinical studies [252,253], allosteric mTORC1 inhibitors (e.g., rapamycin and rapamycin analogs/rapalogs such as Everolimus and Temsirolimus) have been ineffective in patients with prostate cancer, owing to their inability to suppress AKT activity and a number of adverse side effects [17,254].